Navigation Links
Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye
Date:5/22/2013

tein degradation.   Daiichi Sankyo has brought a small molecule from this collaboration, through preclinical development, recently filed an IND, and intends to begin a Phase 1 clinical study of the orally bioavailable study drug, which is aimed at targeting ubiquitin protein ligase. Since dysfunction in the ubiquitin/proteasome system has been shown to be associated with cancer, selective small molecules targeting ubiquitin ligases may be a novel approach to treatment.

About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders.  Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for RA with its partner AstraZeneca; R343, an inhaled SYK inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus – both of which are undergoing Phase 2 clinical trials; and, R348, a topical JAK/SYK inhibitor, expected to enter into a Phase 2 clinical trial for the treatment of chronic dry eye. 

This press release contains "forward-looking" statements, including, without limitation, statements related to Rigel's future product candidate pipeline and strategy, its programs in dry eye and oncology, and the further development of, and the therapeutic and commercial potential of fostamatinib, partnered with AstraZeneca.   Any statements contained in this press release th
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
2. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
3. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
4. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
5. ResMed Inc. Announces Plan To Initiate Dividend And Update On Chief Executive Officer Succession
6. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
7. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
8. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
9. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
10. ESTEVE Announces Publication of Key Preclinical Data for a Novel Oral, First-in-class New Chemical Entity (NCE) Sigma-1 Receptor Antagonist (E-52862), that has Completed Phase I and Initiated its Phase II Clinical Trial Program
11. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... WASHINGTON , July 31, 2014  According to ... Medicaid Services, the 2015 average monthly Medicare Part D ... figure far lower than was originally projected, the Pharmaceutical ... Part D program continues to be a bright spot ... competing choices in each region and using cutting edge, ...
(Date:7/31/2014)... 31, 2014  ResMed Inc. (NYSE: RMD ) ... fiscal year ended June 30, 2014.  Revenue for the quarter ... 30, 2013 (a 1 percent decrease on a constant currency ... percent compared to the quarter ended June 30, 2013. Diluted ... of 22 percent compared to the quarter ended June 30, ...
(Date:7/31/2014)... , July 31, 2014  Cepheid (NASDAQ: CPHD ... the following conferences, and invited investors to participate via webcast. ... New York, NY Wednesday, August 13, ... Health Care Conference, New York, NY ... Accessing Live Webcasts To access the live webcasts ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Cepheid to Webcast Upcoming Financial Presentations 2
... March 18th publication in prominent peer-reviewed journal ... drug-resistant staph infection, EVANSTON, Ill., March ... aureus (MRSA) using a,rapid molecular diagnostic test ... to research published in the Annals of ...
... 2b in Second Quarter of 2008 - ... Tomorrow at 8:00 a.m. Eastern Time -, SAN ... ) today announced positive preliminary results from its,ongoing Phase ... transcriptase inhibitor (NNRTI), in,patients with human immunodeficiency virus (HIV)., ...
Cached Medicine Technology:Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention 2Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention 3Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 2Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 3Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 4
(Date:8/1/2014)... Blindness is a reversible ailment these days . ... despite well-meaning efforts, still have a long way to go ... blindness that does not involve any kind of health risk ... takes the “slack” from the mainstream by providing a cure ... , Alternative health specialist Kevin Richardson actually has the ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 AAGL, ... gynecologic endoscopic surgery, is pleased to announce a ... the United States and Europe, which strongly recommends ... to surgeons an endoscopic dry lab for training ... their endoscopic surgery skills. , Endoscopy is the ...
(Date:8/1/2014)... Surftech athletes Jack Bark and Carter Graves won ... past weekend in Hawaii in commanding fashion shattering world ... were all on stock Surftech Bark Commanders. The event ... this year were treated to 6-10 foot seas and ... as well as very fast. , The win ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 iFitDress.com, a ... unveiled its new collection of 2014 silver bridesmaid ... are manufactured according to the latest fashion trends. What’s ... 15 to 55 percent off. , iFitDress.com is ... it deals in not only silver bridesmaid gowns, but ...
(Date:7/31/2014)... over the age of 65 face numerous barriers to ... against poverty and higher rates of asthma with worse ... of Annals of Allergy, Asthma and Immunology , ... Asthma and Immunology (ACAAI), outlines the challenges faced by ... to improve their care. , "Allergists want ...
Breaking Medicine News(10 mins):Health News:The Miracle Cure Review | The Unbeatable Secret to Reversing Any Vision Problem – Vinamy.com 2Health News:AAGL Announces It Has Joined With Other Medical Societies to Encourage Hospitals Teaching Endoscopic Surgery to Establish Simulator Labs for Training 2Health News:Surftech Bark Commander Sweeps Molokai2Oahu Stock Paddleboard Division 2Health News:iFitDress.com: Beautiful Silver Bridesmaid Dresses at Promotional Prices 2Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3
... , WASHINGTON, Sept. 11 The ... and Economic Studies: , , WHO : ... Johns Hopkins University Bloomberg School of Public Health, Drexel University School ... , , WHAT : The Joint Center,s ...
... disease progression , FRIDAY, Sept. 11 (HealthDay News) -- Two ... body,s ability to repair itself when afflicted with multiple sclerosis, ... , "Most MS genetic studies have looked at disease susceptibility ... not," study author Allan Bieber, a Mayo Clinic neuroscientist, said ...
... legs as they get older? As we age it becomes harder ... and increases the likelihood of falls and fractures. New research is ... A team of Nottingham researchers has already shown that when ... young. Now they,ve found that the suppression of muscle breakdown, which ...
... oxygen-carrying component of hemoglobin, the protein that makes blood ... and energy metabolism within the cell. Heme levels are ... prevents cell growth and division; excessive amounts of heme ... Pennsylvania School of Medicine have discovered a molecular circuit ...
... , , PHOENIX, Sept. 11 ... Health Plan Arizona President Tom Lescault co-hosts "Senior Focus" every other ... producer of the "Valley Views" show, Lescault interviews local experts on ... ",Senior Focus, is about seniors, for seniors and reflective of seniors, ...
... , , , ... and Union Activism , , SILVER ... convention starting Sept. 14, AFL-CIO will honor the work of UAN,s ... work helped make workers, voices heard. , , ...
Cached Medicine News:Health News:Joint Center to Unveil Health Reform Study Providing Answers: What Is the Cost of Not Addressing Racial Health Disparities? 2Health News:Muscle: 'Hard to build, easy to lose' as you age 2Health News:Inner workings of molecular thermostat point to pathways to fight diabetes, obesity 2Health News:Inner workings of molecular thermostat point to pathways to fight diabetes, obesity 3Health News:SCAN Health Plan CEO Tom Lescault Hosts Biweekly 'Senior Focus' Show on KOY-1230AM, Seeks Input from Area Seniors 2Health News:UAN Nurse Among Political Activists To Be Honored by AFL-CIO 2
For the quantitative determination of high density lipoprotein (HDL) in human serum....
Ready to use liquid single reagent for automated chemistry analyzers. Linearity to 1000 mmol/L...
... Intended for the ... in plasma. Two vials, ... Enzymatic, alphaketoglutarate. Uses NADPH ... other plasma compounds. Reaction: ...
The ProteomeLab PA 800 resolves and quantifies proteins by their isoelectric point and molecular weight, generates high-resolution peptide maps and carbohydrate profiles and provides front-end separa...
Medicine Products: